Author:
Thyssen Jacob P,Schmid-Grendelmeier Peter
Reference11 articles.
1. Biologics for treatment of atopic dermatitis: current status and future prospect;Ratchataswan;J Allergy Clin Immunol Pract,2021
2. Treatment of atopic dermatitis with biologics and Janus kinase inhibitors;Thyssen;Lancet,2021
3. The OX40 axis is associated with both systemic and local involvement in atopic dermatitis;Elsner;Acta Derm Venereol,2020
4. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study;Guttman-Yassky;Lancet,2022
5. Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2). European Academy of Dermatology and Venereology; Milan, Italy; Sept 7–10, 2022 (abstr 3456).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献